JO
Jude Onyia
Chief Scientific Officer

Jude Onyia insider trades: Neurocrine Biosciences (NBIX) stock sales

Chief Scientific Officer, Neurocrine Biosciences Last trade Jun 1, 2026 30 Form 4 filings
$3.5M
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
14
Open-market trades
since 2022
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Jude reports to the SEC

Open-market buys and sales

14 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 1, 2026NBIX↓ Sell$1.8M
May 27, 2026NBIX↓ Sell$1.7M
Jul 9, 2025NBIX↓ Sell$7.8M
Jul 2, 2025NBIX↓ Sell$2.6M
Feb 13, 2025NBIX↓ Sell$336K
Jan 31, 2025NBIX↓ Sell$19K
Nov 29, 2024NBIX↓ Sell$294K
Feb 13, 2024NBIX↓ Sell$190K
Jan 31, 2024NBIX↓ Sell$18K
Nov 29, 2023NBIX↓ Sell$265K
Aug 21, 2023NBIX↓ Sell$343K
Feb 7, 2023NBIX↓ Sell$461K
Jan 31, 2023NBIX↓ Sell$14K
Nov 29, 2022NBIX↓ Sell$284K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other NBIX insiders

Open-market trades in the last 12 months

About Jude Onyia's insider trades

Jude Onyia is Chief Scientific Officer at Neurocrine Biosciences (NBIX). Since Nov 29, 2022, Jude has reported no open-market purchases and 14 sales worth $16.2M on SEC Form 4. In the last 12 months: 2 sales ($3.5M).

Their filings also include grants and awards (12 filings), option exercises (10 filings), shares withheld for taxes (4 filings), gifts (4 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBIX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.